Vasomedical Announces Launch of Its Online Company Store

WESTBURY, N.Y., Jan. 10, 2011 /PRNewswire/ -- Vasomedical, Inc. ("Vasomedical") (OTC Bulletin Board: VASO), a global provider of medical devices and a leader in noninvasive treatment of ischemic cardiac diseases, today announced its launch of online company store at http://shop.vasomedical.com.  The introduction of the store will enable the Company's EECP® customers to source product information and facilitate the placement of orders for accessories and supplies electronically.  The store is also expected to generate new sales for our BIOX™ Holter and ambulatory blood pressure monitors as well as the EZ ECG™ and EZ O2™ oximeters in our patient management product line to new and existing customers. The store, designed to improve the efficiency of business flow, may be also accessed from the Company web site at www.vasomedical.com.  The Company will in the future distribute promotional vouchers for discount to registered online customers.

"The launching of the Company's online store and the recent launch of our EECP® iPhone App, which provides crucial information and support for patients, physicians, and therapists, signify the company's commitment to use the latest technologies to support its customers and to create additional B2B opportunities for growth in today's market," stated Larry Liebman, Vice President of Sales and Marketing.  "Potential patients can also use the iPhone App to identify EECP® provider locations where they can access the therapy in the U.S. and overseas," he concluded.

About Vasomedical

Vasomedical, Inc. is primarily engaged in designing, manufacturing, marketing and supporting EECP® external counterpulsation systems based on the Company's proprietary technology. EECP® therapy is a non-invasive, outpatient therapy for the treatment of diseases of the cardiovascular system currently indicated for use in cases of angina, cardiogenic shock, acute myocardial infarction and congestive heart failure. The therapy serves to increase circulation in areas of the heart with less than adequate blood supply and may restore systemic vascular function. The Company provides hospitals, clinics and private practices with EECP® equipment, treatment guidance and a staff training and maintenance program designed to provide optimal patient outcomes. EECP® is a registered trademark for Vasomedical's enhanced external counterpulsation system.   Through its sales representative agreement with GE Healthcare, the Company is also engaged as an exclusive sales representative for certain GE Healthcare products. Additional information is available on the Company's website at www.vasomedical.com.

VasoHealthcare™, a wholly owned subsidiary of Vasomedical Inc. is a professional sales representation company offering vendors an alternative third party sales channel. Additional information is available at www.vasohealthcare.com.

Except for historical information contained in this release, the matters discussed are forward-looking statements that involve risks and uncertainties. When used in this release, words such as "anticipates", "believes", "could", "estimates", "expects", "may", "plans", "potential" and "intends" and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of the Company's management, as well as assumptions made by and information currently available to the Company's management. Among the factors that could cause actual results to differ materially are the following: the effect of business and economic conditions; the effect of the dramatic changes taking place in the healthcare environment; the impact of competitive procedures and products and their pricing; medical insurance reimbursement policies; unexpected manufacturing or supplier problems; unforeseen difficulties and delays in the conduct of clinical trials and other product development programs; the actions of regulatory authorities and third-party payers in the United States and overseas; uncertainties about the acceptance of a novel therapeutic modality by the medical community; continuation of the GEHC agreement; and the risk factors reported from time to time in the Company's SEC reports.  The Company undertakes no obligation to update forward-looking statements as a result of future events or developments.

SOURCE Vasomedical, Inc.